Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from BCAL Diagnostics Limited ( (AU:BDX) ).
BCAL Diagnostics Limited has launched BREASTESTplus™, a non-invasive diagnostic test designed to enhance breast cancer detection in women with dense breast tissue. This launch marks a significant milestone for the company, aligning with recent policy changes in breast screening and generating initial commercial sales. The product is now available in multiple clinics and supported by a strategic partnership with Cancer Care Associates and the Sydney Breast Clinic, expanding its market reach and integration into specialist workflows.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited operates in the healthcare industry, focusing on developing innovative diagnostic solutions. The company has launched its first commercial product, BREASTESTplus™, a lipid-based diagnostic test aimed at improving breast cancer detection, particularly in women with high breast density.
Average Trading Volume: 153,004
Technical Sentiment Signal: Sell
Current Market Cap: A$20.49M
See more data about BDX stock on TipRanks’ Stock Analysis page.